Monopar Therapeutics (MNPR) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurogene (NGNE) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 2.6% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with -81.6% for NGNE. Monopar Therapeutics is the larger company by market cap ($549.6 million vs $545.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | NGNE |
|---|---|---|
| Share price | $81.89 | $27.26 |
| Market cap | $549.63M | $545.51M |
| 1-day change | -2.49% | +2.87% |
| YTD return | +28.61% | +28.64% |
| 1-year return | -14.80% | +2.59% |
| 5-year return | +242.08% | -81.65% |
| EPS (TTM) | $-2.20 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $43.66 |
| 52-week low | $50.07 | $15.93 |
| Distance from 52-week high | -34.40% | -37.56% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +58.66% | +185.69% |
| Average volume | 213.15K | 247.13K |
| Shares outstanding | 6.71M | 20.01M |
| Employees | 22 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed MNPR by 17.4 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
MNPR vs NGNE FAQ
Which is bigger, Monopar Therapeutics or Neurogene?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $549.63M compared with $545.51M for Neurogene (NGNE).
Which stock has performed better over the past year, MNPR or NGNE?
NGNE returned +2.59% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.